Squadron Capital Management’s InMed Pharmaceuticals INM Stock Holding History

Squadron Capital Management’s Portfolio INM Stock Details INM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$504K	Buy	+325,000	New	+$359K	0.16%	41

Other funds holding INM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Squadron Capital Management's INM Position: Q2 2026 in Review

Squadron Capital Management opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 325,000 shares worth $504K. The stake represents 0.16% of the portfolio and ranks #41 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

Squadron Capital Management held 325,000 shares of InMed Pharmaceuticals worth $504K as of Q2 2026.
InMed Pharmaceuticals was a new Squadron Capital Management position in Q2 2026.
InMed Pharmaceuticals made up 0.16% of Squadron Capital Management's portfolio in Q2 2026, its #41 holding.
20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.